Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
TECH 
Bio-Techne Corp (TECH)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
04/01/2025: TECH (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
AI Based Fundamental Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Analysis of Past Performance
Type Stock | Historic Profit -55.14% | Avg. Invested days 24 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 04/01/2025 |
Key Highlights
Company Size Mid-Cap Stock | Market Capitalization 9.07B USD | Price to earnings Ratio 58.52 | 1Y Target Price 83.95 |
Price to earnings Ratio 58.52 | 1Y Target Price 83.95 | ||
Volume (30-day avg) 1887670 | Beta 1.29 | 52 Weeks Range 56.60 - 85.29 | Updated Date 04/1/2025 |
52 Weeks Range 56.60 - 85.29 | Updated Date 04/1/2025 | ||
Dividends yield (FY) 0.55% | Basic EPS (TTM) 0.98 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin 13.22% | Operating Margin (TTM) 17.76% |
Management Effectiveness
Return on Assets (TTM) 5.68% | Return on Equity (TTM) 7.83% |
Valuation
Trailing PE 58.52 | Forward PE 26.25 | Enterprise Value 9283906560 | Price to Sales(TTM) 7.76 |
Enterprise Value 9283906560 | Price to Sales(TTM) 7.76 | ||
Enterprise Value to Revenue 7.94 | Enterprise Value to EBITDA 30.93 | Shares Outstanding 158088000 | Shares Floating 156269675 |
Shares Outstanding 158088000 | Shares Floating 156269675 | ||
Percent Insiders 1.05 | Percent Institutions 101.03 |
Analyst Ratings
Rating 4.4 | Target Price 85.26 | Buy 3 | Strong Buy 9 |
Buy 3 | Strong Buy 9 | ||
Hold 3 | Sell - | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
Bio-Techne Corp
Company Overview
History and Background
Bio-Techne Corp was founded in 1981 and has grown through acquisitions and organic growth to become a global leader in providing tools for life science research and diagnostics.
Core Business Areas
- Protein Sciences: Develops and manufactures recombinant proteins, antibodies, immunoassays, and cell culture reagents for research and diagnostics.
- Diagnostics and Genomics: Offers molecular diagnostics, cell and gene therapy solutions, and spatial biology platforms.
Leadership and Structure
Bio-Techne is led by a CEO and has a structured organizational hierarchy with various departments responsible for different aspects of the business (R&D, Sales, Marketing, etc.).
Top Products and Market Share
Key Offerings
- Recombinant Proteins: Used in cell culture, protein analysis, and drug discovery. Market share varies by specific protein and application, but Bio-Techne is a major player. Competitors include Thermo Fisher Scientific (TMO) and Merck KGaA (MKKGY).
- ELISA Kits: Used for quantitative detection of proteins in biological samples. Market share is significant in research and diagnostics. Competitors include Thermo Fisher Scientific (TMO) and Abcam (ABC).
- Spatial Biology Solutions: Provide tools for multi-omic analysis, and spatial analysis of cellular environments and biomarker. Market share varies by specific protein and application, but Bio-Techne has innovative products that provide a competitive advantage. Competitors include NanoString Technologies and 10X Genomics.
Market Dynamics
Industry Overview
The life science tools and diagnostics industry is experiencing growth driven by increasing research funding, advancements in genomics and proteomics, and the growing demand for personalized medicine.
Positioning
Bio-Techne is well-positioned in the industry due to its broad product portfolio, strong brand recognition, and focus on innovation.
Total Addressable Market (TAM)
The global life science tools and reagents market is estimated to be over $75 billion. Bio-Techne captures a portion of this TAM with an emphasis on high-margin product offerings.
Upturn SWOT Analysis
Strengths
- Strong brand recognition
- Broad product portfolio
- Focus on innovation
- Global presence
- Recurring revenue streams
Weaknesses
- High R&D expenses
- Dependence on research funding
- Potential for product obsolescence
- Relatively high price-point for products
Opportunities
- Expansion into emerging markets
- Development of new diagnostic tests
- Strategic acquisitions
- Increased adoption of personalized medicine
Threats
- Competition from larger players
- Economic downturn affecting research funding
- Regulatory changes
- Technological disruptions
Competitors and Market Share
Key Competitors
- TMO
- DHR
- MKKGY
Competitive Landscape
Bio-Techne competes with larger, diversified companies and smaller, specialized players. Its strengths include a strong brand and focus on niche markets.
Major Acquisitions
Asuragen
- Year: 2019
- Acquisition Price (USD millions): 307
- Strategic Rationale: Expanded Bio-Techne's molecular diagnostics portfolio.
Growth Trajectory and Initiatives
Historical Growth: Bio-Techne has experienced consistent revenue and earnings growth through organic growth and strategic acquisitions.
Future Projections: Analysts project continued growth for Bio-Techne driven by its strong market position and innovative products.
Recent Initiatives: Recent initiatives include expanding its diagnostics business, investing in new technologies, and strategic partnerships.
Summary
Bio-Techne is a strong company with a diversified portfolio and consistent growth. Its focus on innovation and strategic acquisitions position it well for the future. However, it faces competition from larger players and potential headwinds from economic downturns.
Similar Companies
DHR
Danaher Corporation
DHR
Danaher Corporation
TMO
Thermo Fisher Scientific Inc
TMO
Thermo Fisher Scientific Inc
WAT
Waters Corporation
WAT
Waters Corporation
Sources and Disclaimers
Data Sources:
- Company SEC filings
- Analyst reports
- Industry publications
- Company website
Disclaimers:
The information provided is for informational purposes only and should not be considered investment advice. Market data is subject to change.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Bio-Techne Corp
Exchange NASDAQ | Headquaters Minneapolis, MN, United States | ||
IPO Launch date 1989-02-09 | CEO, President & Director Mr. Kim Kelderman | ||
Sector Healthcare | Industry Biotechnology | Full time employees 3100 | Website https://www.bio-techne.com |
Full time employees 3100 | Website https://www.bio-techne.com | ||
Bio-Techne Corporation, together with its subsidiaries, develops, manufactures, and sells life science reagents, instruments, and services for the research, diagnostics, and bioprocessing markets worldwide. The company operates through two segments, Protein Sciences, and Diagnostics and Genomics. The Protein Sciences segment develops and manufactures biological reagents used in various aspects of life science research, diagnostics, and cell and gene therapy, such as cytokines and growth factors, antibodies, small molecules, tissue culture sera, and cell selection technologies. This segment also offers proteomic analytical tools for automated western blot and multiplexed ELISA workflow consists of manual and automated protein analysis instruments and immunoassays for use in quantifying proteins in various biological fluids. The Diagnostics and Genomics segment develops and manufactures diagnostic products, including controls, calibrators, and diagnostic assays for regulated diagnostics market, exosome-based molecular diagnostic assays, advanced tissue-based in-situ hybridization assays for spatial genomic and tissue biopsy analysis, and genetic and oncology kits for research and clinical applications; and sells products for genetic carrier screening, oncology diagnostics, molecular controls, and research, as well as instruments and process control products for hematology, blood chemistry and gases, and coagulation controls and reagents used in various diagnostic applications. The company has strategic partnership with ALZpath, Inc. to accelerate breakthroughs in neurodegenerative disease research and treatment, including Alzheimer's disease. The company was formerly known as Techne Corporation and changed its name to Bio-Techne Corporation in November 2014. Bio-Techne Corporation was incorporated in 1976 and is headquartered in Minneapolis, Minnesota.
Upturn is now on iOS and Android!
Experience Upturn on your mobile. Install it now!
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.